Theralymph Kick off meeting

 We were honored to introduce our consortium: Dr Kari Alitalo (Finland), Dr Tatiana Petrova (Switzerland), Dr Miikka Vikkula (Belgium), Dr Agnès Noël (Belgium), Dr Lenka Romeislova (Czeck Republic), Dr Gilles Pagès (France), Dr Taija Makinen (Sweden), Flash Therapeutics (France), the Clinical Investigation Center of Toulouse (France) and Inserm Tranfert.

Introduction : Lymphedema is a disorder of the lymphatic vascular system characterized by impaired lymphatic return and swelling of the extremities and accumulation of undrained interstitial fluid/lymph that results in fibrosis and adipose tissue deposition in the affected area. It can be an inherited condition (primary lymphedema) or occurs after cancer surgery and lymph node removal (secondary lymphedema). It causes a significant morbidity and is a common disabling disease affecting more than 120 million people worldwide, however there is no curative treatment for lymphedema. Therefore, our main objective will be to establish a multiple gene therapy for lymphedema. We will focus on women who developed secondary lymphedema after breast cancer. This meeting will consist in presenting the work teams as well as the distribution of each work packages in Theralymph project.